142 related articles for article (PubMed ID: 37864152)
21. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.
Siva S; Chesson B; Bressel M; Pryor D; Higgs B; Reynolds HM; Hardcastle N; Montgomery R; Vanneste B; Khoo V; Ruben J; Lau E; Hofman MS; De Abreu Lourenco R; Sridharan S; Brook NR; Martin J; Lawrentschuk N; Kron T; Foroudi F
BMC Cancer; 2018 Oct; 18(1):1030. PubMed ID: 30352550
[TBL] [Abstract][Full Text] [Related]
22. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
Palma DA; Olson R; Harrow S; Gaede S; Louie AV; Haasbeek C; Mulroy L; Lock M; Rodrigues GB; Yaremko BP; Schellenberg D; Ahmad B; Griffioen G; Senthi S; Swaminath A; Kopek N; Liu M; Moore K; Currie S; Bauman GS; Warner A; Senan S
Lancet; 2019 May; 393(10185):2051-2058. PubMed ID: 30982687
[TBL] [Abstract][Full Text] [Related]
23. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design.
Doppenberg D; Besselink MG; van Eijck CHJ; Intven MPW; Koerkamp BG; Kazemier G; van Laarhoven HWM; Meijerink M; Molenaar IQ; Nuyttens JJME; van Os R; van Santvoort HC; van Tienhoven G; Verkooijen HM; Versteijne E; Wilmink JW; Lagerwaard FJ; Bruynzeel AME;
BMC Cancer; 2022 Dec; 22(1):1363. PubMed ID: 36581914
[TBL] [Abstract][Full Text] [Related]
25. Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur).
Hitchcock KE; Miller ED; Shi Q; Dixon JG; Gholami S; White SB; Wu C; Goulet CC; George M; Jee KW; Wright CL; Yaeger R; Shergill A; Hong TS; George TJ; O'Reilly EM; Meyerhardt JA; Romesser PB
BMC Cancer; 2024 Feb; 24(1):201. PubMed ID: 38350888
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
[TBL] [Abstract][Full Text] [Related]
27. Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial.
Chang JS; Kim SW; Kim YJ; Kim JY; Park SY; Kim JH; Jang TK; Kim YB
Gynecol Oncol; 2018 Oct; 151(1):39-45. PubMed ID: 30146110
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.
Hannan R; Christensen M; Christie A; Garant A; Pedrosa I; Robles L; Mannala S; Wang C; Hammers H; Arafat W; Courtney K; Bowman IA; Sher D; Ahn C; Cole S; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Dec; 5(6):695-703. PubMed ID: 35985982
[TBL] [Abstract][Full Text] [Related]
29. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Iyengar P; Wardak Z; Gerber DE; Tumati V; Ahn C; Hughes RS; Dowell JE; Cheedella N; Nedzi L; Westover KD; Pulipparacharuvil S; Choy H; Timmerman RD
JAMA Oncol; 2018 Jan; 4(1):e173501. PubMed ID: 28973074
[TBL] [Abstract][Full Text] [Related]
30. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.
Hannan R; Christensen M; Hammers H; Christie A; Paulman B; Lin D; Garant A; Arafat W; Courtney K; Bowman I; Cole S; Sher D; Ahn C; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Apr; 5(2):216-224. PubMed ID: 34986993
[TBL] [Abstract][Full Text] [Related]
31. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.
Siva S; Bressel M; Mai T; Le H; Vinod S; de Silva H; Macdonald S; Skala M; Hardcastle N; Rezo A; Pryor D; Gill S; Higgs B; Wagenfuehr K; Montgomery R; Awad R; Chesson B; Eade T; Wong W; Sasso G; De Abreu Lourenco R; Kron T; Ball D; Neeson P;
JAMA Oncol; 2021 Oct; 7(10):1476-1485. PubMed ID: 34455431
[TBL] [Abstract][Full Text] [Related]
32. Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial.
Chen LC; Chiou WY; Lin HY; Lee MS; Lo YC; Huang LW; Chang CM; Hung TH; Lin CW; Tseng KC; Liu DW; Hsu FC; Hung SK
BMC Cancer; 2019 Mar; 19(1):275. PubMed ID: 30922261
[TBL] [Abstract][Full Text] [Related]
33. Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.
Olson R; Jiang W; Liu M; Bergman A; Schellenberg D; Mou B; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Chng N; Matthews Q; Baker S; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresene S; Tyldesley S
JAMA Oncol; 2022 Nov; 8(11):1644-1650. PubMed ID: 36173619
[TBL] [Abstract][Full Text] [Related]
34. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
35. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
[TBL] [Abstract][Full Text] [Related]
36. Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial.
Olson R; Senan S; Harrow S; Gaede S; Louie A; Haasbeek C; Mulroy L; Lock M; Rodrigues G; Yaremko B; Schellenberg D; Ahmad B; Griffioen G; Senthi S; Swaminath A; Kopek N; Liu M; Moore K; Currie S; Bauman G; Warner A; Palma D
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):943-947. PubMed ID: 31470091
[TBL] [Abstract][Full Text] [Related]
37. Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5.
Olson R; Liu M; Bergman A; Lam S; Hsu F; Mou B; Berrang T; Mestrovic A; Chng N; Hyde D; Matthews Q; Lund C; Glick D; Pai H; Basran P; Carolan H; Valev B; Lefresene S; Tyldesley S; Schellenberg D
BMC Cancer; 2018 Oct; 18(1):954. PubMed ID: 30286739
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness Analysis of Stereotactic Ablative Radiation Therapy in Patients With Oligometastatic Cancer.
Kumar A; Straka C; Courtney PT; Vitzthum L; Riviere P; Murphy JD
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1185-1194. PubMed ID: 33002541
[TBL] [Abstract][Full Text] [Related]
39. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
[TBL] [Abstract][Full Text] [Related]
40. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy.
Hardcastle N; Hofman MS; Lee CY; Callahan J; Selbie L; Foroudi F; Shaw M; Chander S; Lim A; Chesson B; Murphy DG; Kron T; Siva S
Radiat Oncol; 2019 Sep; 14(1):164. PubMed ID: 31488175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
